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The Wnt pathway eﬀector gene TCF7L2 has been linked to type II diabetes, making it important to study the role of Wnt
signaling in diabetes pathogenesis. We examined the expression of multiple Wnt pathway components in pancreases from normal
individualsandtypeIIdiabeticindividuals.MultiplemembersoftheWntsignalingpathway,includingTCF7L2,Wnt2b,β-catenin,
pGSK3β, TCF3, cyclinD1, and c-myc, were undetectable or expressed at low levels in islets from nondiabetic individuals, but were
alsoupregulatedspeciﬁcallyinisletsoftypeIIdiabeticpatients.CultureofpancreatictissueandisletisolationledtoWntactivation
that was reversed by the Wnt antagonist sFRP, demonstrating that Wnt activation in that setting was due to soluble Wnt factors.
These data support a model in which the Wnt pathway plays a dynamic role in the pathogenesis of type II diabetes and suggest
manipulation of Wnt signaling as a new approach to β-cell-directed diabetes therapy.
Copyright © 2008 Seung-Hee Lee et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The β-cell is a major target organ in the pathogenesis
of type II diabetes as evidenced by the fact that overt
diabetes does not occur until β-cell dysfunction/loss has
proceeded to the point where hypersecretion of insulin can
no longer compensate for peripheral insulin resistance [1].
The predominant model of the molecular events leading to
β-cell failure is that the diabetic environment, in particular
chronically high levels of glucose and free fatty acids, has
toxic eﬀects on the β-cell [2]. A number of signaling
pathways have been implicated in β-cell failure, including
insulin signaling [3] and oxidative stress [4].
Wnt signal transduction is one of the central pathways
that control organismal growth and diﬀerentiation [5].
In the best-studied branch of the Wnt pathway, termed
the canonical pathway, Wnts bind to frizzled receptors in
conjunction with LRP family coreceptors. Resultant pathway
activation prevents GSK3-mediated phosphorylation of β-
catenin and its subsequent ubiquitin-mediated degradation.
Stabilized β-catenin translocates into the nucleus where it
interacts with transcription factors of the TCF family to
activate target genes, including c-myc and cyclin D family
members.
In addition to the canonical pathway, an alterna-
tive, noncanonical pathway with multiple branches exists.
A calcium-dependent pathway acts through calcium/cal-
modulin-dependent kinase II (CamKII) primarily to con-
trol cell movement. In some cell types, activation of the
noncanonical pathway leads to activation of the NFAT
transcription factor [6], which plays an important role in the
maintenance of functional β-cells [7].
Wnt signaling is critical in early foregut and pancreatic
development [8–10]. Moreover, homozygous mutation of
LRP5 in mice leads to defective glucose-stimulated insulin
secretion from isolated islets in vitro [11]. Components of
the Wnt pathway are present in the adult pancreas, and
in particular multiple members of the frizzled family of
Wnt receptors have been identiﬁed in the islet [8]. There
are discrepant data on the role of Wnt signaling in mature
islets. While most studies have found little evidence that Wnt
signaling is involved in endocrine diﬀerentiation or in the
a d u l ti s l e t[ 9, 10, 12], there is some evidence for an eﬀect of
Wnt signaling on β-cell replication [13].2 Experimental Diabetes Research
To study the role of Wnt signaling in human diabetes,
we systematically examined components of this pathway
in the pancreas of normal and type II diabetic individu-
als. Strikingly, Wnt2b, which activates the canonical Wnt
pathway, was highly upregulated in type II diabetes. Other
mediators of the Wnt pathway, including pGSK3β,T C F / L e f
factors, c-myc, and cyclinD1, were also induced in type II
diabetes, speciﬁcally in the β-cells. β-catenin, in contrast
to the mouse, in which it is highly expressed in normal
islets [14], was low or absent in normal human islets in
situ. However, it was highly upregulated in an islet-speciﬁc
manner in human type II diabetes. Most α-cells did not
exhibit Wnt pathway activation and instead expressed high
levels of the noncanonical Wnt, Wnt4, which can act to
repress canonical Wnt signaling [15]. The upregulation of
TCF factors, including TCF7L2, is particularly interesting as
linkage studies have identiﬁed a polymorphism in that gene
as being tightly linked to type II diabetes in humans and
there is some evidence that this polymorphism aﬀects β-cell
function [16–20].
Ectopic overexpression of the Wnt target gene c-myc in
mice has been shown to cause β-cell apoptosis and diabetes
[21]. To determine whether c-myc was a candidate for being
an early eﬀector in diabetes pathogenesis, we examined the
eﬀect of high-fat diet on c-myc expression in the murine
pancreas. Interestingly, mice fed a high-fat diet for three
monthsexhibitedupregulatedc-mycatatimewhenthemice
were only mildly obese and not yet diabetic.
The ﬁnding that the Wnt pathway is activated in human
type II diabetes and that the Wnt target gene c-myc is also
upregulated early in progression to diabetes in rodents has
important implications for understanding the mechanism
of β-cell compensation and failure in diabetes and provides
impetus for the development of new therapies targeted to
that pathway.
2. METHODS
2.1. Tissue
Paraﬃn-embedded specimens from human pancreases (5
nondiabetic and 9 type II diabetic) were previously
described [22]. Freshly isolated and cultured pancreases
from three nondiabetic individuals were obtained from the
Islet Resource center in (Seattle, Wash, USA) immediately
prior to islet isolation. These pancreases were obtained
postmortem by UNOS and shipped to Seattle in University
of Wisconsin solution (UW solution). Specimens were
collected in 4% paraformaldehyde (PFA) and shipped to
us overnight followed by 30% sucrose/PBS, embedded in
OCT freezing media (Sakura, Calif, USA) and snap-frozen at
−80◦C. Isolated human islets (cultured islets) were obtained
through the Islet Procurement Resource Program (JDRF).
Islets were shipped in CMRL 1066 medium with serum-
free supplements. Upon arrival, islets were ﬁxed in PFA or
washed and cultured in suspension in RPMI supplemented
with 5.5mM glucose, penicillin (100U/mL), streptomycin
(100ug/mL), and 10% bovine serum. Twenty four hours
later, they were treated with 0, 100, 500ng/mL rhsFRP-
1(R&D systems, Minn, USA) for 48 hours, harvested by
ﬁxing in 4% neutral phosphate-buﬀered formalin, followed
by 30% sucrose/PBS, embedded in OCT freezing media
(Sakura, Calif, USA), and snap-frozen at −80◦C.
Human fetal pancreases at 18–24 gestational weeks were
obtained from Advanced Bioscience Resource, in accordance
with University of California San Diego Institutional Review
Board regulations (cold ischemia 12–24 hours).
Murine pancreases were obtained from anesthetized
Balb/c or C57/bl mice and collected in 4% PFA followed by
paraﬃn embedding.
Preparation of nonendocrine pancreatic cells (NEPCs)
clusters was as described [23]. The unpuriﬁed islet fractions
and Cobe bag fractions were obtained from the Universities
of Edmonton, Minnesota, Miami, Washington, the Whittier
Institute for Diabetes, and the City of Hope Medical Center.
2.2. Immuno-histochemistry
Both paraﬃn and frozen samples were sectioned to a mean
thickness of 5μm, washed four times with PBS, treated
with 0.3% Triton in PBS for 10 minutes, and incubated in
blocking solution (PBS with 0.1% Triton X-100/5% normal
goat serum) for 30 minutes at room temperature. They were
then treated by alcohol series and antigen retrieval with
CitriSolvTM(FisherScientiﬁc,Pa,USA).Sectionswereincu-
bated in an antibody solution overnight at 4◦Ca sd e s c r i b e d
Table 1. For ﬂuorescent imaging, slides were incubated with
Alexa488 (MolecularProbs,Ore,USA)/Rhodamine orAlexa
596 (Jackson Immuno Research, 1:300) ﬂuor-labeled anti-
Goat/mouse/rabbit for 45 minutes at room temperature.
TheyweremountedinVectashield(VectorLabs,Burlingame,
Calif, USA). Digital images of stained sections were captured
using a ﬂuorescence microscope with a digital camera
(Nikon, Tokyo, Japan) and deconvoluted (nearest neighbor)
using SlideBook software (Intelligent Imaging Innovations,
Denver, Colo, USA). Confocal microscopy was performed
with an MRC 1024MP laser scanning microscope (Bio-
Rad Laboratories, Inc., Richmond, Calif, USA) equipped
with krypton/argon laser and a Millenia-Tsunami two-
photon Ti-Sapphire femtosecond laser system (Spectra-
Physics, Mountain View, Calif, USA). Fluorescent intensity
signals in confocal images from slides from nondiabetic and
type II diabetic patients were scored blindly and quantitated
using Image J histogram analysis. Statistical analysis was
performed using Student’s t-test to determine mean +/−SE.
2.3. Westernblot
Whole-cell extracts were prepared by incubation in lysis
buﬀer (50mM Tris, pH 8, 150mM NaCl, 5mM EDTA,
100mg/mL PMSF, 1mg/mL aprotinin, 1% Triton X-100)
for 30 minutes on ice, followed by 15 minutes of cen-
trifugation at 12000g, 4◦C as previously described [24].
Extracts were mixed with loading buﬀer and electrophoresed
on 4–15% acrylamide gel (ReadyGel Bio-Rad Laborato-
ries, Inc. Hercules, Calif, USA) in Tris/glycine/SDS buﬀer.Seung-Hee Lee et al. 3
Table 1: Antibodies.
Antibody Cat. No. Supplier Conc.
Amylase SC-12821 Santa Cruz 1:300
β-catenin SC-7963 Santa Cruz 1:200
β-catenin SC-7199 Santa Cruz 1:200
β-catenin 610154 Pharmingen 1:200
c-myc 554205 Pharmingen 1:200
c-myc NCL-CMYC Novocastra 1:100
Cyclin D1 SC-718 Santa Cruz 1:200
E-cadherin SC-7870 Santa Cruz 1:200
γ-catenin SC-8415 Santa Cruz 1:200
γ-catenin SC-7900 Santa Cruz 1:200
Glucagon G-2654 Sigma 1:1000
Glucagon AB932 Chemicon 1:500
Insulin SC-8033 Santa Cruz 1:200
Insulin SC-9168 Santa Cruz 1:200
Insulin I7660 US Biological 1:200
Pdx-1 Dr. Chris Wright 1:1000
pGSK3β SC-11757 Santa Cruz 1:200
sFRP-1 AF1384 R&D 1:200
Somatostatin SC-13099 Santa Cruz 1:200
TCF-3 SC-8635 Santa Cruz 1:200
TCF7L2 SC-8631 Santa Cruz 1:200
Wnt2b AF3900 R&D 1:100
Wnt4 AF475 R&D 1:100
Proteins were transferred onto double nitrocellulose mem-
branes (Immobilon-Psq, Millipore, Bedford, Mass, USA)
in Tris/glycine/methanol buﬀer for 1 hour at 100V. After
overnight blocking in PBS-Tween (PBST) with 3% milk,
membrane was incubated for 2 hours at room temper-
ature with antibodies: anti-β-catenin (Pharmingen), anti-
CK19 (cytokeratin-19)(DAKO),anti-Actin (Sigma,StLouis,
Mo, USA). After extensive washing in PBST, the mem-
brane was incubated with secondary antibody conjugated
to horseradish peroxidase diluted 1:2000 (Amersham/GE,
Buckinghamshire, UK), washed in PBST, and revealed by
ECL (Amersham/GE, Buckinghamshire, UK).
2.4. Mousestudies
Male C57BL/6J mice were purchased from Harlan Sprague
Dawley, Inc. (Indianapolis, Ind, USA). The animals were
obtained at 4 weeks of age weighing 17.9–21.2g at the
start of the study and kept four per cage on a 12:12-hour
light dark schedule. The study was approved by the UCSD
IACUC. One week after arrival, mice were divided into two
groups and were fed either a high-fat diet (Research Diets,
New Brunswick, NJ, USA) or received continuous feeding
of a normal diet for up to 14 weeks. The high-fat diet
consisted of 45% fat, 35% carbohydrate, and 20% protein
(4.73Kcal/g), whereas the normal diet contained 5% fat,
57% carbohydrate, and 18% protein (3.4Kcal/g). A caveat
to high-fat feeding experiments is the possibility that a high-
fat diet diﬀers from normal chow in multiple constituents,
potentially confounding results [25].
For intraperitoneal glucose tolerance test (IPGTT), 8-
hour fasted mice received an intraperitoneal injection with
D-glucose (1.5g/kg). Blood samples were obtained from
the tail vein immediately before and at 15, 30, 60, 90, and
120 minutes after the glucose load. Blood glucose levels
were measured with a Precision Xtra TM glucometer (Abbott
Laboratories, Alameda, Calif, USA).
3. RESULTS
3.1. TCF7L2isupregulatedinisletsof
typeIIdiabeticpatients
Recently, TCF7L2 has been genetically linked to type II
diabetes in multiple populations [16–19]. However, the
mechanism by which it contributes to diabetes pathogenesis
isunknown.ThemRNAlevelofTCF7L2ishigherincultured
isolated islets from type II patients versus normal individuals
[20], but expression in situ has not been examined. We
found that TCF7L2 protein was barely detectable in the
pancreasofnormalindividuals,butitwashighlyupregulated
in an islet-speciﬁc manner in patients with type II diabetes
(Figures1(a)–1(e)). In addition, the expression of TCF3,
which has not been linked to type II diabetes, was also
upregulated (Figures 1(f)–1(j)).
3.2. Wnt2bisupregulatedintypeIIdiabetes
Because TCF7L2 is both an eﬀector as well as a downstream
target of Wnt signaling [26], the induction of TCF factors
suggested that a more global activation of Wnt signaling
may be occurring. To test that hypothesis, we examined the
expression of soluble Wnt factors and the initiators of Wnt
signaling. Based upon the reported pattern of expression of
soluble Wnt factor mRNA in the pancreas, we examined
Wnt2b, which was a good candidate as its RNA has been
reportedtobepresentinisolatedislets[8,27].Innondiabetic
individuals, little or no Wnt2b expression was detectable
(Figures 2(a), 2(b), 2(c)). However, there was dramatic
upregulation in the islets of type II diabetics. Robust
expression of Wnt2b occurred in both β-cells (Figures 2(c),
2(d), 2(e)) and α-cells (not shown) of diabetic patients.
3.3. Humanβ-cellslackdetectableβ-catenin
expressionbutitisstronglyupregulated
intypeIIdiabetes
Activation of frizzled receptors by soluble Wnts results in the
stabilization of β-catenin. β-catenin in human islets of all
ﬁve nondiabetic individuals examined was markedly lower
thaninthesurroundingexocrinetissue,whereitwasstrongly
expressed (Figures 2(f)–2(h), Supplementary Figures 1(a),
1(b) available online at doi:10.1155/2008/728763). The same
pattern was observed in the human fetal pancreas, with high
levels of β-catenin expression in nonendocrine epithelial
cells and very low levels in endocrine cells (Supplementary4 Experimental Diabetes Research
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Figure 1: Expression of TCF factors in type II diabetes. TCF7L2 (red in (a)–(d))and TCF3 (red in (f)–(i))are absent from islets of nondiabetic
individuals (a), (b), (f), and (g), but are present in islets from type II diabetics (c), (d), (h), and (i). Islets are identiﬁed by insulin (green in
(b), (d), (g), and (i)). Quantitation of TCF7L2 (e) and TCF3 (j) expressions in nondiabetic (n = 4) and type II (n = 7) islets: error bars =
mean +/−s.e.m. ∗P<. 05. Scale bars = 50μm.
Figures 1(c), 1(d)). Colocalization studies with PDX-1
revealed that β-catenin was substantially restricted to nonen-
docrine PDX-1 positive, cells in the human fetal pancreas
(Supplementary Figure 1(e)). Because PDX-1 serves as a
precursor for both exocrine and endocrine compartments,
β-catenin expression must be repressed during human, but
not murine, endocrine diﬀerentiation.
To determine whether β-catenin plays a role in β-cell
dysfunction and/or loss in human diabetes, its expression
was examined in the pancreases of 9 patients with type II
diabetes. In contrast with nondiabetic pancreases (Figures
2(f)–2(h)), it was strongly expressed in the islets of all 9
patients,toalevelapproximatelyhalfthatofthesurrounding
exocrine tissue (Figures 2(h)–2(j)). In contrast, there was
no noticeable eﬀect of type II diabetes on the expression
of E-cadherin, which is the major islet cadherin and may
also inﬂuence the level of β-catenin protein in the cell by
sequestering it from degradation (not shown).
Because β-catenin is regulated by GSK3β, we examined
the state of GSK3β activation in normal and type II
diabetic pancreases. The inactive, phosphorylated form of
GSK3β,p G S K 3 β, that leads to stabilization of β-catenin, was
limited to islets in both nondiabetic and diabetic individuals
(Supplementary Figure 2). In type II diabetics, 95% of islets
expressed pGSK3β, while 80% of islets from nondiabetic
individuals expressed pGSK3β. Thus, the majority of normal
islets expressed pGSK3β despite having low or undetectable
levels of β-catenin, suggesting that the upregulation of β-
catenin in islets is not controlled in a simple way by the level
of pGSK3β.
3.4. γ-cateninisexpressedinhumanβ-,butnotα-,cells
T h el o wl e v e lo fβ-catenin in normal human islets in vivo
prompted us to investigate whether another molecule might
be substituting for it in mediating its signaling and/or struc-
tural roles in the β-cell. Lower organisms such as Drosophila
have a single cadherin-binding catenin, Armadillo. However,
in mammals, there are two such catenins, β-a n dγ-catenin,
the latter also called plakoglobin [28]. In murine β-cells, γ-
catenin was upregulated when β-catenin was deleted, but
this was not noted to have any functional signiﬁcance
[10]. In the adult human pancreas, we found that γ-
catenin was expressed in a highly selective manner in β-
cells (Supplementary Figures 1(f)–1(h)), in contrast to α-
cells and the surrounding exocrine tissue, where it was low
or undetectable (Supplementary Figures 1(i)–1(k)). Thus, α-
cells do not appear to exhibit high level expression of either
catenin.
The pattern of catenin expression in the adult was
mirrored in the human fetal pancreas, with γ-catenin being
expressed in β-, but not α-cells (Supplementary Figures 1(l)–
1(q)). Interestingly, in the human fetal pancreas, γ-catenin
was also expressed in nonendocrine PDX-1 positive cells,
beingabsentinPDX-1negativecells(SupplementaryFigures
1(r)–1(u)). Thus, in the human fetal pancreas, β-a n dγ-
catenin are both expressed in PDX-1 expressing progenitors,
but are inversely regulated as those progenitors diverge to
form mature exocrine and β-cells.
3.5. TerminaleffectorsofWntsignalingare
upregulatedinhumantypeIIdiabetes
TCF/LEF factors activate a number of terminal eﬀectors
of Wnt signaling. A well-studied member of that group is
c-myc [29]. Strikingly, c-myc was expressed in the islets
from pancreases from patients with type II diabetes, but not
in islets from nondiabetic individuals (Figures 2(p)–2(s)).
Despite the role of c-myc in promoting cell proliferation,
no increase in islet cell proliferation was observed, as
measured by Ki67 staining (data not shown). In addition
to c-myc, cyclinD1 is an important regulator of prolifer-
ation that is induced by Wnt signaling [30]. It was also
highly upregulated in the islets of type II diabetic patients
(Figures 2(k)–2(o)).Seung-Hee Lee et al. 5
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Figure 2: Expression of Wnt2b, β-catenin, cyclinD1, and c-myc in type II diabetes. Wnt2b (red in (a), (b), (d), and (e)), β-catenin (red in (f),
(g), (i), and (j)), cyclinD1 (red in (k), (l), (n), and (o)), and c-myc (red in (q) and (s)) are absent from islets of nondiabetic individuals (a),
(b), (f), (g), (k), (l), (p) and (q), but are present in islets from type II diabetics (d), (e), (i), (j), (n), (o), (r), and (s). Islets are identiﬁed by
insulin (green in (a), (d), (f), (i), (p), and (r)) or glucagon (l) and (o) and are outlined by a dashed line in (g) to better demonstrate the
absence of β-catenin. Quantitation of Wnt2b (c), β-catenin (h), and cyclinD1 (m) expression in non-diabetic (n = 5) and type II (n = 7)
islets: error bars = mean +/− s.e.m. ∗P<. 05. Scale bars = 100μm except for f.g.i.j which are 50μm.
3.6. Wnttargetexpressionislimitedtoβ-cells,
withα-cellsbeingunaffected
While upregulation of Wnt2b occurred throughout the islet,
activation of Wnt downstream signaling was limited to β-
cells, with α-cells in type II diabetic islets lacking expression
of activation markers, including cyclinD1 (Figures 2(m)–
2(o)). The lack of Wnt signaling in α-cells is interesting,
as signiﬁcant α-cell hyperplasia was observed in the type
II diabetic pancreases (Figures 3(a), 3(b)) and is consistent
with previous reports of the eﬀe c to ft y p eI Id i a b e t e so nt h e
endocrine pancreas [31].
Mechanistically, the fact that Wnt2b was upregulated in
α-cells, but downstream signaling was not activated, sug-
gestedthatthepathwayisdefectiveorrepressedinthosecells.
Occasional α-cells expressing a low level of cyclinD1 and c-
myc was more consistent with a repressor being present than
withα-cells having a completely defective pathway. Members
of the Wnt family that mediate noncanonical Wnt signaling
repress signaling through the canonical pathway under some
circumstances [15]. Thus, we studied the expression of
the noncanonical Wnt, Wnt4, which microarray studies
had suggested was expressed at a high level in human
islets (unpublished). Consistent with the model, Wnt4 was
expressed in α-, but not β-cells (Figures 3(c)–3(f)).
3.7. Isletisolationmimicstheeffectof
typeIIdiabetesonβ-cateninexpression
To pursue the role of Wnt activation in the islet, it would
b ed e s i r a b l et oh a v ea ni nv i t r om o d e l .T h u s ,w ee x a m i n e d
Wnt activation in isolated islets. Surprisingly, when cultured
human islets were examined by Western blotting, β-catenin,
which is low or absent in the islet compared with surround-
ing tissue in situ, was expressed at a higher level than in the
nonendocrine pancreatic cells (NEPCs) [23]( Figure 4(a)).
To determine whether this was due to the process of
islet isolation or subsequent in vitro culture in medium
containing fetal bovine serum, we examined fragments from
whole pancreas that were ﬁxed following transport using
the bilayer method to the islet isolation center [32], but
prior to islet isolation itself. In those fragments, β-catenin
induction occurred to a similar extent as in isolated islets (cf.
Figures 4(b), 4(c)) marking it as an early event in the tissue
procurement process. To determine whether upregulation of6 Experimental Diabetes Research
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Figure 3: α-cell hyperplasia in type II diabetes and expression of
Wnt4 in α-cells. Immunostaining of pancreas from nondiabetic
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demonstrates α-cell hyperplasia in type II diabetes (a) and (b) and
expression of Wnt4 (red in (c)–(f)) predominantly in α-cells (c)–
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β-catenin in isolated islets indicated active canonical Wnt
signaling, we examined them for c-myc expression, ﬁnding
that it was highly expressed (Figures 4(k), 4(m)).
3.8. TheWntinhibitorsFRPreducesβ-cateninand
c-mycexpressioninhumanislets
The model suggested by the data in type II diabetes and in
isolated islets is that upregulation of soluble Wnts by some
aspectoftheenvironmentintypeIIdiabeticindividualsorin
isolatedisletsthenactivatestheWntsignalingpathway.How-
ever, alternative mechanisms for Wnt pathway activation are
possible as well. For example, insulin, which is hypersecreted
at early stages in type II diabetes in response to end organ
unresponsiveness, is a potent inhibitor of GSK3 and thus a
potential activator of the Wnt pathway [33].
To distinguish between Wnt-dependent and Wnt-
independent activation of downstream signaling, human
islets were cultured with or without soluble frizzled receptor
protein (sFRP), which represses Wnt signaling by seques-
tration of Wnt proteins [34]. sFRP bound at high levels
to islets (Figure 4(g)). Consistent with canonical activation
of the pathway by secreted Wnts interacting with frizzled
receptors, sFRP caused a reduction in both cytoplasmic and
membrane-associated β-catenin (Figures 4(h)–4(j)) and c-
myc (Figures 4(k)–4(m)). Thus, a Wnt inhibitor restored
human beta cells to the β-catenin and c-myc negative state
associated with normal tissue in situ, demonstrating clearly
that Wnt pathway activation is occurring and suggesting that
the process of Wnt activation in isolated islets mimics what
occurs in type II diabetes.
Activation of Wnt signaling in harvested islets has impli-
cations for islet transplantation. To determine whether Wnt
activation was reversible following transplantation, three
cultured islet preparations (containing some nonendocrine
material) were transplanted under the kidney capsule of
immunodeﬁcient mice and analyzed three months later. β-
catenin expression in the islets had reverted back to levels
much lower than in the surrounding duct structures within
the graft (Figures 4(d), 4(e)), similar to the pattern found in
the normal human pancreas.
3.9. Wnteffectorsareinverselycorrelatedwith
insulinexpressionintypeIIdiabetes
In two pancreases from patients with type II diabetes but
none of the nondiabetic controls, there were two distinct
types of islets, exhibiting a 3.5-fold diﬀerence in the level
of insulin expression in the β-cells. Interestingly, β-catenin
upregulation was present to a much greater degree in β-cells
with diminished insulin expression (Figures 5(a)–5(e)). This
indicates either that local factors are generated as a result
of the diabetic environment or that islets are heterogeneous,
withsomebeingmoresusceptibletoeﬀectsoffactorsthatare
homogeneously distributed.
Since γ-a n dβ-catenin were inversely regulated in the
normal pancreas, the upregulation in some type II diabetic
pancreasesofβ-catenininisletswithlowerinsulinexpression
suggested the possibility that γ-catenin expression might
be downregulated in those islets. This proved to be true
(Figures 5(j), 5(k)). Thus, the weak insulin-expressing islets
present in the diabetic state mimicked the pattern of catenin
expression in the exocrine pancreas, where β-catenin protein
is abundant and γ-catenin is not expressed.
To pursue the ﬁnding that β-cells with low-insulin
expression had a pattern of catenin expression resembling
that in the exocrine pancreas, pancreas sections were
immunostained for the acinar marker amylase as well as
insulin, revealing that low-insulin β-cells coexpressed amy-
lase (Figures 5(f), 5(g), 5(h)). The insulin/amylase double-
positive cells expressed PDX-1 (Figure 5(i)), which in the
adult pancreas is restricted to β-cells and is never expressed
in mature acinar cells, indicating that the weak insulin
expression was not artifactual.The ﬁnding of cellsexpressing
both insulin and amylase is consistent with a proposal by
some investigators that endocrine and exocrine cells can
transdiﬀerentiate [35]. Insulin-amylase double-positive cells
have been found in models of β-cell regeneration [36–38].
To further explore whether the areas containing the
insulin/amylase double-positive cells arose by alteration of
preexisting β-cells or by induction of insulin expression inSeung-Hee Lee et al. 7
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preexisting exocrine cells, as has been described in some β-
cell regeneration models [37–39], we examined those areas
forglucagonexpression.Consistently,highlevelsofglucagon
andalackofamylasewereobservedinallα-cells,whetherthe
islets exhibited high or low insulin expression (Figure 5(l)).
Thus, the α-cells appeared normal, even in low-insulin
expressing islets. Overall, these data suggest that one eﬀect
of type II diabetes on the β-cell is to promote an aberrant
diﬀerentiation state in which β-cells lose insulin expression
and begin to express exocrine markers.
3.10. ExpressionoftheWnttargetgenec-mycis
anearlyresponsetohigh-fatdiet
To begin to address the question of whether Wnt activation
was an early or late event in diabetes pathogenesis, we moved
to a mouse model. Mice were placed on either a normal
chow (low-fat) or high-fat diet and harvested pancreases
were examined for c-myc expression after 12 weeks of high-
fatdiet,atwhichpointthemicewereobese(Figure 6(g)),but
had a normal fasting blood glucose. Intraperitoneal glucose
tolerance tests revealed mild glucose intolerance, being
marginally statistically diﬀerent from the control group only
at the 90-minute time point (P = .04) (Figure 6(h)).
Consistent with previous studies [14], we found that the
murine pancreas exhibited a pattern of β-catenin expression
opposite from that in the human, with mouse islets express-
ing high levels of β-catenin and the exocrine pancreas having
less β-catenin (Figures 6(a)–6(c)). However, the high level of
β-catenin expression even in the normal chow group did not
reﬂect Wnt activation, as c-myc was not detectable in either
the endocrine or exocrine pancreas (Figures 6(d), 6(f)). In
contrast, the high-fat fed animals exhibited a high level of
c-myc in islets (Figures 6(e), 6(f)). Additionally, some but
not all ducts in the high-fat fed animals exhibited c-myc
expression (Figure 6(e)). Unlike in the human, where we
were able to identify Wnt2b and Wnt4 as being expressed
in the islet, we have thus far been unable to identify the
soluble Wnts responsible for activating Wnt targets in the
adult mouse pancreas. However, combined with the human
data, the results in the mouse suggest that obesity alone may
be suﬃcient to induce Wnt activation, which would mark it
as an early event in the pathogenesis of type II diabetes.
4. DISCUSSION
The studies presented here are based primarily upon the
examination of pancreas samples from normal and type
II diabetic humans, from which we conclude that Wnt
signaling eﬀectors are upregulated in the islets in type II
diabetes.
A number of components in the Wnt pathway have
been found to be associated with type II diabetes or obesity
in linkage studies. Our ﬁnding that TCF3 and TCF7L2
are induced in islets from type II diabetics is particularly
interesting in light of recent linkage association studies in
which TCF7L2 has been identiﬁed as the gene most strongly
linked to type II diabetes [17–19]. TCF7L2 is also a direct
downstream target of β-catenin [26] ,w h i c hw ef o u n dt ob e
induced in type II diabetes. Similarly, lrp5, a component of
theWntreceptorsignalingcomplexisassociatedwithobesity
phenotypes [40] and Wnt5b is associated with susceptibility
to type II diabetes [41]. Wnt pathway genes have also been
linked to type I diabetes [42]. Whether the involvement of
Wnt signaling on predisposition to diabetes occurs through
eﬀects in the islet or in peripheral tissue has not been
determined. However, we and others have established that c-
myc has substantial eﬀects on β-cell function, exempliﬁed by
its ability to repress hormone expression and to induce both
proliferation and apoptosis [43, 44].
Of relevance to the speciﬁcity of the changes in Wnt
signaling that were observed, alterations in the level of
Wnt pathway components in the human pancreas were
restricted to the islet, with little change in the exocrine
pancreas. Consistent changes in Wnt pathway components
were evident despite the fact that the human pancreases
were obtained from widely divergent patients. The “normal”
controlsweremostlynotfromyounghealthyindividuals,but
rather from older individuals with signiﬁcant illness [22].
This is likely to have minimized the extent of any diﬀerences,
so it is striking that we still observed large changes in the
expression of Wnt pathway components in the samples from
diabetic patients.
While no single Wnt downstream eﬀector or pathway
intermediate is absolutely speciﬁc for the Wnt pathway given
the extensive cross-talk between Wnt and other signaling
pathways, the evidence for activation of Wnt signaling in
β-cells is strong, with pathway components at all levels
being aﬀected, including upregulation of β-catenin, TCF3,
TCF7L2, cyclinD1, c-myc, and Wnt2b. Upregulation of
Wnt2b is important, as there cannot be true pathway
activation in the absence of an initiating signal. The down-
regulation of the downstream target c-myc by sFRP provides
direct evidence that Wnt activation through a soluble Wnt
occurs in islets, though the stimulus for upregulation of the
soluble Wnt may or may not be the same in isolated islets
a n dt y p eI Id i a b e t e s .
While Wnt2b was induced throughout the islet, canon-
ical Wnt activation was found predominantly in β-cells. In
α-cells, the pathway remained inactive, a state that correlated
with α-cell-speciﬁc expression of Wnt4, a member of the
Wnt family that mediates noncanonical signaling and that
can repress canonical signaling [15, 45]. While we observed
changes in expression of Wnt2b and Wnt4, the Wnt family is
large. Attempts to examine other members are ongoing but
have been limited by the lack of high-quality antibodies. It
is likely that additional complexity will be revealed as other
members of the Wnt family and other components of the
pathway are examined.
Wnt binding to frizzled receptors leads to stabilization
of β-catenin by inactivation of GSK3β, which is itself under
complex control, including distinct regulation by growth
factors as well as Wnt signaling [46]. Of relevance to
diabetes, GSK3β is inhibited by insulin signaling through
the PI3 kinase pathway [47]. Thus, hyperinsulinemia, a
classic feature of type II diabetes that occurs early in the
disease, could lead quite directly to upregulation of β-
catenin.Interestingly,ithasbeenproposed, onthebasisofitsSeung-Hee Lee et al. 9
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involvementininsulinsignaling,thatinhibitorsofGSK3may
be eﬀective in improving insulin sensitivity in rodent models
of type II diabetes [48]. However, based on data presented
here,suchinhibitorsmightleadtoWntactivationintheislet.
The inverse correlation between Wnt pathway activation and
insulin gene expression that we found suggests that, at least
in the long term, Wnt activation could be deleterious to
islet function. In contrast to what is believed to occur in
the peripheral tissue, it is possible that Wnt inhibition and
consequent activation of GSK3β could have positive eﬀects
on islet function. Thus, in one tissue, GSK3 inhibition might
prove beneﬁcial, while in another, harmful.
β-cell speciﬁc Wnt eﬀector upregulation occurred in the
context of striking diﬀerential expression of Wnt pathway
components in the endocrine versus exocrine pancreas
in nondiabetic humans and mice, as well as signiﬁcant
interspecies diﬀerences. The best example of this is β-
catenin, which was expressed in an inverse pattern in the
normal human and murine pancreases. In humans, β-
catenin was virtually absent in islets and expressed at high
levels in the exocrine pancreas, while in the murine pancreas
the reverse pattern was found. In the human exocrine
pancreas, β-catenin appears to be localized to the plasma
membrane, which is a pattern that is consistent with its10 Experimental Diabetes Research
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role in mediating connections between cadherins and the
actin cytoskeleton. Despite decreased β-catenin expression
in islets, only the human endocrine pancreas expressed high
levels of phosphorylated GSK3β, which in the canonical
model of Wnt signaling should have led to stabilization
and upregulation of β-catenin. Unfortunately, we were
unable to assess the expression of the unphosphorylated,
active form of GSK3β due to limitations of the available
antibodies.
γ-catenin was expressed in a converse fashion to β-
catenin in islets from nondiabetic individuals. Further, the
dynamic regulation of β-a n dγ-catenin, with β-catenin
being induced and γ-catenin repressed in islets with acti-
vated Wnt signaling, suggests that these molecules play an
important role in diabetes pathogenesis. In some tissues, β-
and γ-catenin act antagonistically, with β-catenin tending
to promote cell growth, while γ-catenin acts as a tumor
suppressor [49, 50]. While both β-a n dγ-catenin can bind
to TCF/LEF transcription factors, γ-catenin does so much
less eﬃciently [51]. In addition, we have found that TCF
genes are speciﬁcally activated by β-, but not γ-catenin
(unpublished results).
Wntpathwayactivationinisolatedisletshasimplications
for islet transplantation. Islet dysfunction and loss is a majorSeung-Hee Lee et al. 11
problem in islet transplantation, both in the immediate
posttransplant period and chronically [52]. The ﬁnding that
the process of isolation induces some changes that are also
seen in type II diabetes raises the possibility that the isolation
process could have deleterious eﬀects. If, as indicated by
the known undesirable eﬀects of c-myc on islet biology
[43, 44, 53], Wnt activation has a negative eﬀect on β-
cell function and/or survival, inhibiting that upregulation in
transplanted islets could be beneﬁcial. The demonstration
here that β-catenin upregulation is reversible following renal
subcapsular transplantation or by inhibiting Wnt signaling
with sFRP provides a direct means of testing that hypothesis
and could also provide a model system to study the eﬀects of
Wnt pathway activation in type II diabetes.
A question of major importance is the functional role
of Wnt signaling in diabetes pathogenesis, that is, is it part
of an adaptive response or a pathologic response? These are
not mutuallyexclusive. Onepossibility is thatWntactivation
plays an adaptive role early in type II diabetes, perhaps in
promoting β-cell proliferation [13], while chronic pathway
activationleadstocelldeath,awell-recognizedfunctionofc-
myc [44, 54]. The mouse studies suggest but do not yet prove
deﬁnitively that Wnt activation could be an early event in
diabetes pathogenesis that is associated with high-fat diet.
The striking activation of Wnt signaling in human type
II diabetes, albeit in a small number of patients, provides
insight into the molecular eﬀects of diabetes on the β-cell
and oﬀers a novel potential route to prevent β-cell failure.
Direct manipulation of the activation state of the pathway is
required to dissect out the complex roles of the Wnt pathway
in diabetes. In addition, diabetes has been shown to be a
strong risk factor for cancer, including pancreatic cancer
[55,56]. Moreover, overexpression of β-catenininthemouse
pancreas promoted pancreatic cancer [57]. Thus, activated
Wnt signaling may be a critical mechanism of pathogenesis
common to both diabetes and pancreatic cancer.
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